249 related articles for article (PubMed ID: 37421275)
1. Sex Differences in the Effectiveness of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril-Valsartan for the Treatment of Heart Failure.
Sohani ZN; Behlouli H; de Moura CS; Abrahamowicz M; Pilote L
J Am Heart Assoc; 2023 Jul; 12(14):e028865. PubMed ID: 37421275
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Sacubitril/Valsartan Therapy for Acute Decompensated Heart Failure with Reduced Ejection Fraction during the Vulnerable Phase: A Multicenter, Assessor-Blinded, Prospective, Observational, Cohort Study.
He Y; Lu X; Zheng Y; Song M; Shen B; Nienaber CA; Chen G; Wu F; Zheng J; Zhang W; Wang Y; Li X; Wen H; Yu X; Zhou Y
Cardiology; 2021; 146(3):335-344. PubMed ID: 33780933
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.
Lee WC; Liao TW; Chen TY; Fang HY; Fang YN; Chen HC; Lin YS; Chang SH; Chen MC
Cardiovasc Drugs Ther; 2024 Jun; 38(3):505-515. PubMed ID: 36609948
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
[TBL] [Abstract][Full Text] [Related]
5. Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction.
Xi Q; Chen Z; Li T; Wang L
J Int Med Res; 2022 Jan; 50(1):3000605211067909. PubMed ID: 34986674
[TBL] [Abstract][Full Text] [Related]
6. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Mou Y; Qin L; Wang L; Guo Y; Zhang X; Yu J
Altern Ther Health Med; 2024 Apr; 30(4):190-197. PubMed ID: 37917889
[TBL] [Abstract][Full Text] [Related]
8. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
McMurray JJV; Jackson AM; Lam CSP; Redfield MM; Anand IS; Ge J; Lefkowitz MP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Rizkala AR; Sabarwal SV; Shah AM; Shah SJ; Shi VC; van Veldhuisen DJ; Zannad F; Zile MR; Cikes M; Goncalvesova E; Katova T; Kosztin A; Lelonek M; Sweitzer N; Vardeny O; Claggett B; Jhund PS; Solomon SD
Circulation; 2020 Feb; 141(5):338-351. PubMed ID: 31736337
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
Foà A; Vaduganathan M; Claggett BL; Pabon MA; Lu H; Pfeffer MA; Packer M; Vardeny O; Rouleau JL; Lefkowitz M; Mentz RJ; Jhund PS; Desai AS; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2024 May; 83(18):1731-1739. PubMed ID: 38537919
[TBL] [Abstract][Full Text] [Related]
12. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
Wang R; Ye H; Zhao Y; Wei J; Wang Y; Zhang X; Wang L
BMC Med; 2022 Dec; 20(1):487. PubMed ID: 36527023
[TBL] [Abstract][Full Text] [Related]
13. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
14. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
Jia R; Zhang X; Xu Y; Zheng Z; Jiang L; Zhang X; Sun C; Wu X; Li S; Raj A; Sun D
Eur J Pharmacol; 2022 Aug; 928():175053. PubMed ID: 35709921
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis.
Yang HR; Xu XD; Shaikh AS; Zhou BT
Ann Pharmacother; 2023 Aug; 57(8):907-917. PubMed ID: 36475871
[TBL] [Abstract][Full Text] [Related]
16. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
Curtain JP; Adamson C; Docherty KF; Jhund PS; Desai AS; Lefkowitz MP; Rizkala AR; Rouleau JL; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJV
JACC Heart Fail; 2023 Jul; 11(7):749-759. PubMed ID: 37407154
[TBL] [Abstract][Full Text] [Related]
17. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
[TBL] [Abstract][Full Text] [Related]
18. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
20. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
Dargad RR; Prajapati MR; Dargad RR; Parekh JD
Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S102-S110. PubMed ID: 30122239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]